Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes

Journal of Geriatric Oncology

Volumn 5, Issue 3, 2014, Pages 299-306

  Bammer, Christoph ^a   Sperr, Wolfgang R ^b   Kemmler, Georg ^a   Wimazal, Friedrich ^c   Nösslinger, Thomas ^d   Schönmetzler, Anabel ^d   Krieger, Otto ^e   Pfeilstöcker, Michael ^d,f   Valent, Peter ^d,f   Stauder, Reinhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^d HANUSCH HOSPITAL   (Austria)

^e Hospital of Elisabethinen   (Austria)

^f LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Age; Assessment; Comorbidities; MDS; Myelodysplastic syndromes; Prognosis; Sex; Survival

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRIA; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; FEMALE; HEART ARRHYTHMIA; HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SEX DIFFERENCE; SOLID TUMOR; EPIDEMIOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; SEVERITY OF ILLNESS INDEX; SEX RATIO; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AUSTRIA; COMORBIDITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREVALENCE; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84904989476     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2014.02.002     Document Type: Article

References (38)

1. Malcovati L., Hellström-Lindberg E., Bowen D., Adès L., Cermak J., Del Cañizo C., et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European Leukemia Net. Blood 2013, 122(17):2943-2964.
2. Valent P., Horny H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31(6):727-736.
3. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012, 87(7):692-701.
4. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25(23):3503-3510.
5. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
6. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Solé F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120(12):2454-2465.
7. Nosslinger T., Tuchler H., Germing U., Sperr W.R., Krieger O., Haase D., et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2010, 21(1):120-125.
8. Itzykson R., Thépot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117(2):403-411.
9. Kantarjian H., O'Brien S., Ravandi F., Cortes J., Shan J., Bennett J.M., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer 2008, 113(6):1351-1361.
10. Morel P., Declercq C., Hebbar M., Bauters F., Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol 1996, 94(1):116-119.
11. Wang R., Gross C.P., Halene S., Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 2009, 33(12):1594-1598.
12. Zipperer E., Pelz D., Nachtkamp K., Kuendgen A., Strupp C., Gattermann N., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009, 94(5):729-732.
13. Sperr W.R., Wimazal F., Kundi M., Baumgartner C., Nösslinger T., Makrai A., et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS study group. Ann Oncol 2010, 21(1):114-119.
14. Breccia M., Federico V., Latagliata R., Mercanti C., D'Elia G.M., Cannella L., et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res 2011, 35(2):159-162.
15. Della Porta M.G., Malcovati L., Strupp C., Ambaglio I., Kuendgen A., Zipperer E., et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96(3):441-449.
16. Naqvi K., Garcia-Manero G., Sardesai S., Oh J., Vigil C.E., Pierce S., et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 2011, 29(16):2240-2246.
17. Sperr W.R., Kundi M., Wimazal F., Nosslinger T., Schonmetzler-Makrai A., Stauder R., et al. Proposed score for survival of patients with myelodysplastic syndromes. Eur J Clin Invest 2013, 43(11):1120-1128.
18. Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106(8):2912-2919.
19. Extermann M., Wedding U. Comorbidity and geriatric assessment for older patients with hematologic malignancies: a review of the evidence. J Geriatr Oncol 2012, 3(1):49-57.
20. Hamaker M.E., Vos A.G., Smorenburg C.H., de Rooij S.E., van Munster B.C. The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. Oncologist 2012, 17(11):1439-1449.
21. Soubeyran P., Fonck M., Blanc-Bisson C., Blanc J.F., Ceccaldi J., Mertens C., et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012, 30(15):1829-1834.
22. Hamaker M.E., Prins M.C., Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy - - a systematic review. Leuk Res 2014, 38(3):275-283. Epub ahead of print.
23. Stauder R. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Ann Hematol 2012, 91(9):1333-1343.
24. Germing U., Strupp C., Kundgen A., Bowen D., Aul C., Haas R., et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 2004, 89(8):905-910.
25. de Swart L.L., Smith A.A., Fenaux P.P., Symeonidis A., Hellström-Lindberg E., Sanz G., et al. Disease-management of Low- and intermediate-1 risk myelodysplastic syndromes: report on 800 newly diagnosed MDS patients from the European Leukemia Net MDS registry. Blood 2010, 116. [Suppl., abstr. 2917].
26. European myelodysplastic syndrome (MDS) registry of the European LeukaemiaNet [last accessed Nov 12], Available from:. http://www.eumds.org/.
27. Stauder R., Nosslinger T., Pfeilstocker M., Sperr W.R., Wimazal F., Krieger O., et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw 2008, 6(9):927-934.
28. Goldberg S.L., Chen E., Corral M., Guo A., Mody-Patel N., Pecora A.L., et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010, 28(17):2847-2852.
29. Della Porta M.G., Malcovati L. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. Haematologica 2009, 94(5):602-606.
30. Sorror M.L. How I assess comorbidities before hematopoietic cell transplantation. Blood 2013, 121(15):2854-2863.
31. Valentiny C., Kemmler G., Stauder R. Age, sex and gender impact multidimensional geriatric assessment in elderly cancer patients. J Geriatr Oncol 2012, 3(1):17-23.
32. Pal S.K., Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010, 28(26):4086-4093.
33. Pfeilstocker M., Tuchler H., Schonmetzler A., Nosslinger T., Pittermann E. Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for myelodysplastic syndromes. Leuk Res 2012, 36(2):132-139.
34. Deschler B., Ihorst G., Platzbecker U., Germing U., Marz E., de Figuerido M., et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 2013, 98(2):208-216.
35. Lee S.J., Lindquist K., Segal M.R., Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006, 295(7):801-808.
36. Gattermann N., Kundgen A., Kellermann L., Zeffel M., Paessens B., Germing U. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany. Eur J Haematol 2013.
37. Pleyer L., Stauder R., Burgstaller S., Schreder M., Tinchon C., Pfeilstocker M., et al. Azacitidine in patients with WHO-defined AML - - results of 155 patients from the Austrian azacitidine registry of the AGMT-study group. J Hematol Oncol 2013, 6(1):32.
38. Wildes T.M., Ruwe A.P., Fournier C., Gao F., Carson K.R., Piccirillo J.F., et al. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J Geriatr Oncol 2013, 4(3):227-234.